Ajanta Pharma is currently trading at Rs 1682.50, up by 12.85 points or 0.77% from its previous closing of Rs. 1669.65 on the BSE.
The scrip opened at Rs. 1670.05 and has touched a high and low of Rs. 1710.00 and Rs. 1651.55 respectively. So far 31705 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1720.00 on 12-Aug-2015 and a 52 week low of Rs. 580.00 on 13-Aug-2014.
Last one week high and low of the scrip stood at Rs. 1720.00 and Rs. 1635.50 respectively. The current market cap of the company is Rs. 14998.05 crore.
The promoters holding in the company stood at 73.78% while Institutions and Non-Institutions held 9.96% and 16.25% respectively.
Ajanta Pharma has reported 38.04% rise in its net profit at Rs 81.06 crore for the quarter ended June 30, 2015 as compared to Rs 58.72 crore for the same quarter in the previous year. The company’s total income has increased by 19.55% to Rs 354.11 crore for the quarter under review from Rs 296.18 crore for the corresponding quarter of the previous year.
On the consolidated basis, the company has reported 40.53% rise in its net after taxes, Minority Interest and Share of Profit/(Loss) of Associates at Rs 83.84 crore for the quarter ended June 30, 2015 as compared to Rs 59.66 crore for the same quarter in the previous year. Total income of the company has increased by 21.97% at Rs 397.93 crore for quarter under review as compared to Rs 326.25 crore for the quarter ended June 30, 2014.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: